BioRestorative Therapies, Inc. (BRTX)
BRTX moved a median of -0.82% 30 minutes after news, and -0.63% by the close. How BRTX actually reacts to news — the realized, point-in-time move the market made, measured across 209 labeled events over the last three years with zero look-ahead.
BRTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.30% | 33% | 193 |
| 30-min | -0.82% | 38% | 203 |
| 60-min | -1.42% | 36% | 205 |
| to close | -0.63% | 42% | 206 |
| Middle 50% of BRTX reactions | -3.26% to +1.03% |
|---|---|
| Median reaction (30-min) | -0.82% |
| Measured reactions | 209 |
Half of all BioRestorative Therapies, Inc. news events land between -3.26% and +1.03% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BRTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BRTX's baseline. Nothing else.
Recent BRTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K BioRestorative Therapies For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.41% | |
| Form 8-K BioRestorative Therapies For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | -3.96% | |
| Form 8-K/A BioRestorative Therapies For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | -3.96% | |
| BioRestorative Therapies Announces Reverse Stock Split | Press release | GlobeNewswire | +7.56% | -12.38% | |
| Form 8-K BioRestorative Therapies For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.64% | |
| Form 8-K BioRestorative Therapies For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +7.56% | -12.38% | |
| Form 8-K BioRestorative Therapies For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +1.82% | -1.41% | |
| Form 8-K BioRestorative Therapies For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -2.01% | -3.93% | |
| Form NT 10-Q BioRestorative Therapies For: Jun 30 | SEC filing · Form NT | SEC EDGAR | -2.01% | -3.93% | |
| Form 8-K BioRestorative Therapies For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +4.73% | +0.94% | |
| BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform | Press release | GlobeNewswire | +0.18% | -4.14% | |
| BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth | Press release | GlobeNewswire | +5.41% | +10.70% | |
| Form 8-K BioRestorative Therapies For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +2.57% | +11.71% | |
| Form 8-K BioRestorative Therapies For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | -5.49% | |
| Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) | Press release | Canada Newswire | -0.17% | +8.22% | |
| BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data | Press release | GlobeNewswire | +5.57% | -3.37% | |
| Form 10-Q BioRestorative Therapies For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.74% | +1.16% | |
| BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals | Press release | GlobeNewswire | +0.82% | +1.36% | |
| BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease | Press release | GlobeNewswire | -1.86% | -6.00% | |
| Form 8-K BioRestorative Therapies For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -3.63% | -1.22% | |
| BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform | Press release | GlobeNewswire | -1.99% | +9.17% | |
| Form EFFECT BioRestorative Therapies | SEC filing · Form EFFECT | SEC EDGAR | -0.58% | -10.16% | |
| Form POS AM BioRestorative Therapies | SEC filing · Form POS | SEC EDGAR | +1.88% | +1.32% | |
| Form 8-K BioRestorative Therapies For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | -2.87% | -0.04% | |
| BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform | Press release | GlobeNewswire | -1.91% | -6.48% | |
| Form POS AM BioRestorative Therapies | SEC filing · Form POS | SEC EDGAR | -1.91% | -6.48% | |
| Form DEF 14A BioRestorative Therapies For: May 26 | SEC filing · Form DEF | SEC EDGAR | +1.02% | -3.53% | |
| BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform | Press release | GlobeNewswire | +0.04% | +5.12% | |
| Form PRE 14A BioRestorative Therapies For: May 26 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -2.71% | |
| BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease | Press release | GlobeNewswire | -2.76% | -3.75% | |
| Form 10-K BioRestorative Therapies For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.50% | -0.93% | |
| BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease | Press release | GlobeNewswire | +1.08% | +6.75% | |
| BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 | Press release | GlobeNewswire | -1.73% | -4.01% | |
| BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy | Press release | GlobeNewswire | -2.07% | +4.77% | |
| BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs | Press release | GlobeNewswire | -8.92% | +3.65% | |
| Form 8-K BioRestorative Therapies For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -6.03% | -7.42% | |
| BioRestorative Announces Closing of $5.0 Million Public Offering | Press release | GlobeNewswire | -6.03% | -7.42% | |
| Form EFFECT BioRestorative Therapies | SEC filing · Form EFFECT | SEC EDGAR | -2.52% | +4.96% | |
| BioRestorative Announces Positive Outcome from Type B Meeting with FDA | Press release | GlobeNewswire | -1.52% | -30.07% | |
| BioRestorative Announces Pricing of $5.0 Million Public Offering | Press release | GlobeNewswire | -2.52% | +4.96% | |
| BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease | Press release | GlobeNewswire | -8.36% | -28.58% | |
| Form S-1/A BioRestorative Therapies | SEC filing · Form S-1 | SEC EDGAR | -1.52% | -30.07% | |
| Form S-1 BioRestorative Therapies | SEC filing · Form S-1 | SEC EDGAR | -8.36% | -28.58% | |
| Form EFFECT BioRestorative Therapies | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +1.85% | |
| Form S-1 BioRestorative Therapies | SEC filing · Form S-1 | SEC EDGAR | -0.82% | +17.21% | |
| Form S-8 BioRestorative Therapies | SEC filing · Form S-8 | SEC EDGAR | -0.82% | +17.21% | |
| BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease | Press release | GlobeNewswire | -4.38% | -9.49% | |
| BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.03% | — | |
| Form 10-Q BioRestorative Therapies For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.03% | — | |
| Form 8-K BioRestorative Therapies For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -1.03% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BRTX section they belong to.
Where else BRTX is measured.
BRTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PRECISION THERAPEUTICS INC COMMON (AIPT) | 211 | 0.00% | 46% |
| Amarin Corporation plc - American Depositary Shares (AMRN) | 211 | +0.30% | 55% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 208 | -0.32% | 48% |
| Journey Medical Corporation (DERM) | 208 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioRestorative Therapies, Inc.'s median reaction calculated?
Every labeled BRTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 209 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 38% of BRTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BRTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.